6 results on '"Nicholas G. Panos"'
Search Results
2. Clinical outcomes after 4F-PCC for warfarin-associated ICH and baseline GCS less than or equal to 8
- Author
-
Kristen E, Koehl, Nicholas G, Panos, Gary D, Peksa, and Giles W, Slocum
- Subjects
Emergency Medicine ,Anticoagulants ,Humans ,Glasgow Coma Scale ,International Normalized Ratio ,Warfarin ,General Medicine ,Blood Coagulation Factors ,Cerebral Hemorrhage ,Retrospective Studies - Abstract
There is limited evidence describing the mortality benefit of utilizing 4-factor prothrombin complex concentrate (4F-PCC) in patients presenting with a warfarin-associated intracerebral hemorrhage (ICH) and a Glasgow Coma Scale (GCS) of ≤8. The aim of this study is to determine the potential mortality benefit of 4F-PCC in this patient population.This was a retrospective chart review, performed at a comprehensive stroke center from October 2013 through August 2020. Patients were included if they were ≥ 18 years of age, experienced a spontaneous ICH with baseline GCS ≤ 8, treated with warfarin prior to admission, had a baseline INR ≥ 1.7, and received 4F-PCC for INR normalization due to warfarin-associated ICH. The primary outcome was in-hospital mortality at 30 days.A total of 252 patients received 4F-PCC in the specified time period. Of those patients, 25 patients met inclusion criteria. Sixteen patients (64%) experienced in-hospital mortality. When compared to a historical estimated 80% mortality rate in the studied patient population, there was no statistically significant difference (p = 0.208) in mortality when 4F-PCC was utilized to reverse INR.The administration of 4F-PCC in patients presenting with warfarin-related ICH and GCS ≤ 8 did not result in statistically significant mortality benefit. Our results are limited by study design and sample size. Thus, larger studies are needed to determine if a benefit exists for 4F-PCC in this patient population. Although the results are not statistically significant, our small study suggests that there may be a clinically significant mortality benefit when 4F-PCC is utilized.
- Published
- 2022
3. Factor Xa Inhibitor-Related Intracranial Hemorrhage
- Author
-
Nicholas G. Panos, Aaron M. Cook, Sayona John, G. Morgan Jones, Hallie Kelly, Richard K. Choi, Nirali Kalaria, Jamie M. Rosini, Mathew Jones, Mohammed Rehman, Philip M. Ross, Benjamin Motley, Samantha Delibert, Benjamin P. George, Charles M Andrews, Ron R Neyens, Ryan Martin, Kendra J. Schomer, Michael J. Armahizer, Mehrnaz Pajoumand, Casey C. May, Keaton S. Smetana, Tamara Strohm, Christian Hamm, Laurel Jakubowski, Shaun P. Keegan, Vasisht Srinivasan, Christopher J. Burdick, Omar J. Martinez, Farhad Bahrassa, Scott T. May, K. Ashley Sowers, Eugene I. Lin, Deidre J. Rohaley, Jason Mackey, Lori L. Wetmore, Christine Frick, Meena Thatikunta, Lindsay Urben, Abdalla A. Ammar, Kent A. Owusu, Keith Nguyen, Michael J. Erdman, Brian W. Gilbert, Joshua M. DeMott, Gary D. Peksa, Philip E. Tobias, Ivan Da Silva, Leana N. Mahmoud, Bethany Sheahan, Aimee Gowler Gennaro, Michael A. Pizzi, Gretchen M. Brophy, Dennis J. Rivet, Micheal Strein, Kristine Arandela, Van Hellerslia, and Meghan M. Caylor
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Subarachnoid hemorrhage ,medicine.drug_mechanism_of_action ,Pyridones ,medicine.drug_class ,Factor Xa Inhibitor ,030204 cardiovascular system & hematology ,Hemostatics ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Rivaroxaban ,Risk Factors ,law ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,Hospital Mortality ,Aged ,Retrospective Studies ,Hemostasis ,business.industry ,Anticoagulant ,Length of Stay ,Middle Aged ,Subarachnoid Hemorrhage ,medicine.disease ,Intensive care unit ,Blood Coagulation Factors ,United States ,Hematoma, Subdural ,Treatment Outcome ,Cohort ,Pyrazoles ,Female ,Apixaban ,Intracranial Thrombosis ,Cardiology and Cardiovascular Medicine ,business ,030217 neurology & neurosurgery ,Factor Xa Inhibitors ,medicine.drug ,Cohort study - Abstract
Background: Since the approval of the oral factor Xa inhibitors, there have been concerns regarding the ability to neutralize their anticoagulant effects after intracranial hemorrhage (ICH). Multiple guidelines suggest using prothrombin complex concentrates (PCCs) in these patients on the basis of research that includes a limited number of patients with ICH. Given this, we aimed to evaluate the safety and efficacy of PCCs for factor Xa inhibitor–related ICH in a large, multicenter cohort of patients. Methods: This was a multicenter, retrospective, observational cohort study of patients with apixaban- or rivaroxaban-related ICH who received PCCs between January 1, 2015, and March 1, 2019. The study had 2 primary analysis groups: safety and hemostatic efficacy. The safety analysis evaluated all patients meeting inclusion criteria for the occurrence of a thrombotic event, which were censored at hospital discharge or 30 days after PCC administration. Patients with intracerebral, subarachnoid, or subdural hemorrhages who had at least 1 follow-up image within 24 hours of PCC administration were assessed for hemostatic efficacy. The primary efficacy outcome was the percentage of patients with excellent or good hemostasis on the basis of the modified Sarode criteria. Secondary outcomes included an evaluation of in-hospital mortality, length of stay, infusion-related reactions, and thrombotic event occurrence during multiple predefined periods. Results: A total of 663 patients were included and assessed for safety outcomes. Of these, 433 patients met criteria for hemostatic efficacy evaluation. We observed excellent or good hemostasis in 354 patients (81.8% [95% CI, 77.9–85.2]). Twenty-five (3.8%) patients had a total of 26 thrombotic events, of which 22 occurred in the first 14 days after PCC administration. One patient had documentation of an infusion-related reaction. For the full cohort of patients, in-hospital mortality was 19.0%, and the median intensive care unit and hospital lengths of stay were 2.0 and 6.0 days, respectively. Conclusions: Administration of PCCs after apixaban- and rivaroxaban-related ICH provided a high rate of excellent or good hemostasis (81.8%) coupled with a 3.8% thrombosis rate. Randomized, controlled trials evaluating the clinical efficacy of PCCs in patients with factor Xa inhibitor–related ICH are needed.
- Published
- 2020
4. 4. Coagulopathy Reversal Agents for Intracranial Hemorrhage
- Author
-
Karen Berger, Nicholas G. Panos, and John J. Lewin
- Subjects
business.industry ,Anesthesia ,Coagulopathy ,Medicine ,business ,medicine.disease - Published
- 2019
5. Coagulopathy Reversal Agents for Intracranial Hemorrhage
- Author
-
Karen Berger, Nicholas G. Panos, and John J. Lewin
- Published
- 2018
6. Outcomes associated with transdermal nicotine replacement therapy in a neurosurgery intensive care unit
- Author
-
Keri S. Kim, Nicholas G. Panos, Jeffrey J. Mucksavage, and Eljim P. Tesoro
- Subjects
Male ,Nicotine ,medicine.medical_specialty ,Subarachnoid hemorrhage ,Transdermal Patch ,Neurosurgical Procedures ,law.invention ,law ,medicine ,Humans ,Trauma, Nervous System ,Hospital Mortality ,Nicotinic Agonists ,Retrospective Studies ,Chicago ,Pharmacology ,Intracerebral hemorrhage ,business.industry ,Health Policy ,Smoking ,Middle Aged ,medicine.disease ,Intensive care unit ,Icu admission ,Intensive Care Units ,Treatment Outcome ,Transdermal nicotine ,Anesthesia ,behavior and behavior mechanisms ,Female ,Angiographic vasospasm ,Neurosurgery ,business ,Intracranial Hemorrhages ,medicine.drug - Abstract
Purpose The outcomes associated with transdermal nicotine replacement therapy (NRT) in a neurosurgery intensive care unit (ICU) were studied. Methods Data from pharmacy records, neurosurgery ICU admission logs, and computerized patient charts at the University of Illinois Medical Center at Chicago from January 2001 through August 2008 were reviewed for patients older than 18 years who were admitted to the neurosurgery ICU for neurologic insults. Patients were categorized into three groups: smokers who received transdermal NRT ( n = 114), smokers who did not receive transdermal NRT ( n = 113), and nonsmokers ( n = 113). The primary outcome of this study was unfavorable disposition at discharge from the hospital. Secondary outcomes measured included overall mortality; lengths of hospital and neurosurgery ICU stays; and rates of subarachnoid hemorrhage (SAH) rebleeding, angiographic vasospasm, intracerebral hemorrhage rebleeding, and ischemic stroke. Results Overall, there was no difference in unfavorable discharge disposition among the three groups ( p = 0.17). However, the group who received NRT had higher admission rates of SAH, smoked more cigarettes for a longer period of time, and had longer stays in the neurosurgery ICU and hospital compared with the other groups. All patients who received NRT had prolonged hospital ( p = 0.014) and neurosurgery ICU (p = 0.006) stays compared with those who did not receive NRT. There were no differences in other secondary outcomes among the groups. Conclusion There was no significant difference in unfavorable discharge disposition among neurosurgery ICU patients who were smokers treated with NRT, smokers not treated with NRT, and nonsmokers not treated with NRT.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.